Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
- Status
- UNKNOWN
- Phase
- NA
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Polish Microbiome Map
- Status
- UNKNOWN
- Phase
- N/A
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
- Status
- COMPLETED
- Phase
- N/A
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
- Status
- COMPLETED
- Phase
- N/A
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
- Status
- UNKNOWN
- Phase
- N/A
PVSRIPO in Combination With Nivolumab in Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
DERM Health Economics Study
- Status
- COMPLETED
- Phase
- N/A
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Status
- RECRUITING
- Phase
- PHASE2
Microbiome Immunotherapy Toxicity and Response Evaluation
- Status
- UNKNOWN
- Phase
- N/A
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2